Get the Stockscreener App
0.00
100.00%
-90.00
Merus N V stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$90.00
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$6.83B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
0.00
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$97.14
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
0.00 | 6.83B | 35.93M | -244.56M | -157.31M | -3.95 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Aug-25-25 | Initiated | Alliance Global Partners | Buy |
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
GMAB SEC FilingsGenmab 10-K, 10-Q, 8-K Forms - Stock Titan
Trade Report: Is Merus NV on track to beat earnings2026 Short Interest & Daily Momentum Trading Reports - baoquankhu1.vn
Aug Weekly: Is Merus NV being accumulated by smart money2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
US Market Wrap: What hedge funds are buying Merus NVInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Merus NV Stock: Genmab Acquisition Deal at $97 Per Share Reshapes Biotech Investment Landscape for N - AD HOC NEWS
Bank Watch: Is Merus NV on track to beat earningsWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
Bull Run: Can Merus NV reach all time highs this year2026 Buyback Activity & Safe Entry Zone Tips - baoquankhu1.vn
Wells Fargo Downgrades Merus N.V. (MRUS) - MSN
Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion - MSN
Stock Recap: Can Merus NV reach all time highs this yearRate Hike & Target Return Focused Stock Picks - baoquankhu1.vn
Merus NV Stock (ISIN: NL0011375928) Gains Momentum on Bispecific Antibody Pipeline Progress - AD HOC NEWS
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race - MSN
Growth Review: Is Merus NV a good ESG investment2026 Setups & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Precision Trading with Merus N.v. (MRUS) Risk Zones - Stock Traders Daily
How Merus N.V. stock reacts to bond yieldsTrade Analysis Report & Low Risk Profit Maximizing Plans - Naître et grandir
Dividend Watch: Is Merus NV being accumulated by smart moneyMarket Sentiment Review & Consistent Profit Trade Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Aug Summary: Is Merus NV a good ESG investment2025 Big Picture & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Biotechnology Gem With 7.78% Potential Upside - DirectorsTalk Interviews
Genmab Publishes 2025 Annual Report - GlobeNewswire
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
What is Merus N.V. s 5 year growth outlookWeekly Stock Summary & AI Enhanced Trading Signals - mfd.ru
Targets Report: Will Merus N.V. stock outperform tech sector in 2025Weekly Trade Summary & Reliable Momentum Entry Alerts - mfd.ru
Genmab Prepares For Two Product Launches In 2027, Both From Recent Deals - Citeline News & Insights
Is Merus N.V. stock trading near support levelsJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - mfd.ru
Published on: 2026-02-10 12:58:35 - mfd.ru
Can Merus N.V. reach all time highs this year2025 Major Catalysts & Proven Capital Preservation Methods - mfd.ru
Merus N.V. (MRUS) Stock Analysis: Weighing The 7.78% Potential Upside For Investors - DirectorsTalk Interviews
Merus N.V. (MRUS) Stock Analysis: Exploring the Potential 7.78% Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Downgrade: Is Merus NV gaining market shareJuly 2025 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Growth Recap: What are Can Fite BioPharma Ltd Depositary Receipts technical support levels - baoquankhu1.vn
Aug Ideas: Is Merus NV a turnaround storyJuly 2025 PreEarnings & AI Enhanced Execution Alerts - baoquankhu1.vn
Fourteen option delistings on January 21st - TipRanks
Merus N.V. (MRUS) Stock Analysis: Biotechnology Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Piper Sandler sets $84 target on Merus stock, cites drug potential - MSN
S P Trends: How does Merus NV correlate with Nasdaq2025 Technical Overview & Target Return Focused Picks - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Healthcare Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Gap Down: Is Merus N.V. stock a safe haven assetJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - Bộ Nội Vụ
Aug Breakouts: Why Merus NV stock could benefit from AI revolutionJuly 2025 Final Week & Stock Market Timing Techniques - Bộ Nội Vụ
Risk Report: Will Merus NV stock benefit from M A activityQuarterly Market Summary & Pattern Based Trade Signal System - Bộ Nội Vụ
Aug Shorts: Is Merus NV stock a buy on dipsEarnings Growth Summary & Low Risk Entry Point Tips - Bộ Nội Vụ
(MRUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Published on: 2026-01-13 00:53:02 - Улправда
Merus N.V.Common Shares (NQ: MRUS - FinancialContent
How Merus N.V. stock trades before earnings2025 Market Overview & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Net current asset value per share of Merus N.V. – MUN:2GH - TradingView — Track All Markets
Why Merus N.V. stock attracts high net worth investorsQuarterly Performance Summary & Reliable Entry Point Trade Alerts - ulpravda.ru
Is Merus N.V. (2GH) stock positioned for digital growth eraDay Trading Setups & Free Tools to Monitor Market Corrections - Улправда
Merus N.V. Financial Disclosures & Filings - TradingView — Track All Markets
Merus N.V. (MRUS) Stock Analysis: Exploring a 7.78% Potential Upside Amid Biotech Innovations - DirectorsTalk Interviews
Genmab Announces $2.5 Billion Note Offering for Merus Acquisition - MSN
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):